Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours

  • Tanic, M.
  • Andrés-León, Eduardo
  • Rodríguez-Pinilla, S. M.
  • Márquez-Rodas, I.
  • Cebollero-Presmanes, M.
  • Fernández, V.
  • Osorio, A.
  • Benítez, Javier
  • Martínez-Delgado, B.
[Background] Hereditary breast cancer comprises 5–10% of all breast cancers. Mutations in two high-risk susceptibility genes, BRCA1 and BRCA2, along with rare intermediate-risk genes and common low-penetrance alleles identified, altogether explain no more than 45% of the high-risk breast cancer families, although the majority of cases are unaccounted for and are designated as BRCAX tumours. Micro RNAs have called great attention for classification of different cancer types and have been implicated in a range of important biological processes and are deregulated in cancer pathogenesis., [Methods] Here we have performed an exploratory hypothesis-generating study of miRNA expression profiles in a large series of 66 primary hereditary breast tumours by microarray analysis., [Results] Unsupervised clustering analysis of miRNA molecular profiles revealed distinct subgroups of BRCAX tumours, ‘normal-like’ BRCAX-A, ‘proliferative’ BRCAX-B, ‘BRCA1/2-like’ BRCAX-C and ‘undefined’ BRCAX-D subgroup. These findings introduce a new insight in the biology of hereditary breast cancer, defining specific BRCAX subgroups, which could help in the search for novel susceptibility pathways in hereditary breast cancer., [Conclusion] Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features., We thank all members of the Human Genetics Group and the Immunohistochemistry Unit of the Spanish National Cancer Research Centre for all their support. This work was funded by grants from Spanish Ministry of Health PI11/01059, PI08/1120 and PI12/00070, from the Fundación Mutua Madrileña 2011 and from Fundación Sandra Ibarra 2011., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors

  • Tanic, M.
  • Yanowski, Kira
  • Andrés-León, Eduardo
  • Gómez-López, Gonzalo
  • Rodríguez-Pinilla, S. M.
  • Pisano, David G.
  • Martínez-Delgado, B.
  • Benítez, Javier
Hereditary breast cancer constitutes only 5-10% of all breast cancer cases and is characterized by strong family history of breast and/or other associated cancer types. Only ~ 25% of hereditary breast cancer cases carry a mutation in BRCA1 or BRCA2 gene, while mutations in other rare high and moderate-risk genes and common low penetrance variants may account for additional 20% of the cases. Thus the majority of cases are still unaccounted for and designated as BRCAX tumors. MicroRNAs are small non-coding RNAs that play important roles as regulators of gene expression and are deregulated in cancer. To characterize hereditary breast tumors based on their miRNA expression profiles we performed global microarray miRNA expression profiling on a retrospective cohort of 80 FFPE breast tissues, including 66 hereditary breast tumors (13 BRCA1, 10 BRCA2 and 43 BRCAX), 10 sporadic breast carcinomas and 4 normal breast tissues, using Exiqon miRCURY LNA™ microRNA Array v.11.0. Here we describe in detail the miRNA microarray expression data and tumor samples used for the study of BRCAX tumor heterogeneity (Tanic et al., 2013) and biomarkers associated with positive BRCA1/2 mutation status (Tanic et al., 2014). Additionally, we provide the R code for data preprocessing and quality control., This work was supported by the Asociación Española Contra el Cancer (AECC) and the Spanish Fondo de Investigaciones Sanitarias (grant numbers FIS-PI081298 and FIS-PI081120), by grants from INNPRONTA from the Ministry of Science and Innovation PI11/01059, from the Fundación Mutua Madrileña 2011 (PI BMD), and from the Fundación Sandra Ibarra 2011 (PI BMD). The CIBER de Enfermedades Raras is an initiative of the Instituto de Salud Carlos III (ISCIII). MT had financial support from the Fundación La Caixa call 2008., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression

  • Matamala, Nerea
  • Vargas, Maria Teresa
  • González-Cámpora, Ricardo
  • Arias, José Ignacio
  • Menéndez, Primitiva
  • Andrés-León, Eduardo
  • Yanowsky, Kira
  • Llaneza-Folgueras, Ana
  • Miñambres, Rebeca
  • Martínez-Delgado, B.
  • Benítez, Javier
Emerging evidence suggests that BRCA1 pathway contributes to the behavior of sporadic triple negative breast cancer (TNBC), but little is known about the mechanisms underlying this association. Considering the central role that microRNAs (miRNAs) play in gene expression regulation, the aim of this study was to identify miRNAs specifically deregulated in TNBC and investigate their involvement in BRCA1 regulation. Using locked nucleic acid (LNA)-based microarrays, expression levels of 1919 miRNAs were measured in paraffin-embedded tissues from 122 breast tumors and 11 healthy breast tissue samples. Differential miRNA expression was explored among the main subtypes of breast cancer, and 105 miRNAs were identified as specific for triple negative tumors. In silico prediction revealed that miR-498 and miR-187-5p target BRCA1, and these results were confirmed by luciferase reporter assay. While miR-187-5p was found overexpressed in a luminal B cell line, miR-498 was highly expressed in a triple negative cell line, Hs578T, and its expression was negatively correlated with the levels of BRCA1. We functionally demonstrated that miR-498 inhibits BRCA1 in breast cancer cell lines, and showed that inhibition of miR-498 led to reduced proliferation in the triple negative cell line Hs578T. Our results indicate that miR-498 regulates BRCA1 expression in breast cancer and its overexpression could contribute to the pathogenesis of sporadic TNBC via BRCA1 downregulation., We thank all members of the Human Cancer Genetics Programme of the Spanish National Cancer Research Centre for all their support. We want to particularly acknowledge the patients, the INCLIVA BioBank (PT13/0010/0004) integrated in the Spanish National Biobanks Network, and Pablo Isidro Marrón, coordinator of Biobanco del Principado de Asturias, for their collaboration. This work has been funded by grants from the Spanish Ministry of Economy and Competitiveness (INNPRONTA LIFE project) and FIS PI11/01059 (BM-D)., Peer reviewed